Actinium Pharmaceuticals Appoints Radiopharmaceutical Industry Veteran Sean Maenpaa as Senior Vice President, Business Development

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced the appointment of Sean Maenpaa as Senior Vice President, Business Development, effective October 12, 2026. Mr. Maenpaa will lead the Company's business development activities, including out-licensing, partnering and collaboration transactions, in-licensing opportunities, and broader corporate development strategy.